BioPharma Credit (LSE:BPCR) Total Equity: $1,150.9 Mil (As of Dec. 2025)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
49 GF Score
Price $0.96
GF Value $0.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Total Equity?

BioPharma Credit LSE:BPCR +0.63% 49 Total Equity is $1,150.9 Mil as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review.

BioPharma Credit's total equity for the quarter that ended in Dec. 2025 was $1,150.9 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioPharma Credit Total Equity Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Total Equity Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 1,363.72 1,337.45 1,340.86 1,181.68 1,150.86

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,340.86 1,228.07 1,181.68 1,150.31 1,150.86
LSE:BPCR
49GF Score
BioPharma Credit PLC LSE:BPCR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioPharma Credit's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1168.419-17.557
=1,150.9

BioPharma Credit's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1168.419-17.557
=1,150.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1,150.9 Mil mean?
BioPharma Credit (LSE:BPCR) has a Total Equity of $1,150.9 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for BioPharma Credit and its competitors.
Is BioPharma Credit's Total Equity too high?
BioPharma Credit's current Total Equity is $1,150.9 Mil. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Total Equity compare to BLK and BX?
BioPharma Credit's Total Equity of $1,150.9 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for an Asset Management company?
A good Total Equity depends on the Asset Management industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioPharma Credit and its competitors. BioPharma Credit's current Total Equity is $1,150.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current Total Equity is $1,150.9 Mil. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Total Equity is $1,150.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Total Equity: $1,150.9 Mil
  • GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score

Get the complete analysis for LSE:BPCR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.97
GF Value